Bisphosphonate therapy is commonly prescribed for patients at risk of osteoporosis-related fractures, with oral therapy being the most common form. The therapy works by inhibiting bone resorption and is typically taken on an empty stomach with high adherence. It is important to assess patient eligibility for treatment using a fracture risk assessment tool and to monitor renal function before prescribing intravenous therapy. Treatment should be continued for at least five years orally or three years annually with intravenous therapy before considering a hiatus. Shared decision making is valued by patients considering treatment. Bisphosphonates have been widely used since 1995, with common preparations including alendronate, risedronate, ibandronate, and zoledronate. In the UK, millions of prescriptions for oral bisphosphonates are made each year.
Source link
Bisphosphonates | The BMJ
